Towards precision oncology with patient-derived xenografts

Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013).

CAS  PubMed  Article  Google Scholar 

Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hahn, W. C. et al. An expanded universe of cancer targets. Cell 184, 1142–1155 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

McCoach, C. E. & Bivona, T. G. Engineering multidimensional evolutionary forces to combat cancer. Cancer Discov. 9, 587–604 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020).

CAS  PubMed  Article  Google Scholar 

Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806–1814 (2013).

PubMed  Article  Google Scholar 

Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017).

CAS  PubMed  Article  Google Scholar 

Stripecke, R. et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol. Med. 12, e8662 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474 (2017).

PubMed  Article  Google Scholar 

Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311–316 (2015).

CAS  PubMed  Article  Google Scholar 

Avolio, M. & Trusolino, L. Rational treatment of metastatic colorectal cancer: a reverse tale of men, mice, and culture dishes. Cancer Discov. 11, 1644–1660 (2021).

CAS  PubMed  Article  Google Scholar 

Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hoge, A. C. H. et al. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis. Oncol. 6, 30 (2022).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sun, H. et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat. Commun. 12, 5086 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 13, 335–347 (2016).

CAS  PubMed  Article  Google Scholar 

Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595–2605 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2015).

CAS  PubMed  Article  Google Scholar 

Salehi, S. et al. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Nature 595, 585–590 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dang, H. X. et al. The clonal evolution of metastatic colorectal cancer. Sci. Adv. 6, eaay9691 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548 (2013).

CAS  PubMed  Article  Google Scholar 

Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576–582 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fakih, M. G. et al. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin. Cancer Res. 16, 3786–3794 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Meng, Y. et al. Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. Ann. Palliat. Med. 10, 11255–11264 (2021).

PubMed  Article  Google Scholar 

Cleary, J. M. et al. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest. New Drugs 32, 937–945 (2014).

CAS  PubMed  Article  Google Scholar 

Vlahovic, G. et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest. New Drugs 32, 976–984 (2014).

CAS  PubMed  Article  Google Scholar 

Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843–855 (2018).

CAS  PubMed  Article  Google Scholar 

Marin-Bejar, O. et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell 39, 1135–1149 (2021).

CAS  PubMed  Article  Google Scholar 

Vendramin, R. et al. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. J. Exp. Med. 218, e20210571 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Buczacki, S. J. A. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65–69 (2013).

CAS  PubMed  Article  Google Scholar 

Basak, O. et al. Induced quiescence of Lgr5+ stem cells in intestinal organoids enables differentiation of hormone-producing enteroendocrine cells. Cell Stem Cell 20, 177–190 (2017).

CAS  PubMed  Article  Google Scholar 

Barriga, F. M. et al. Mex3a marks a slowly dividing subpopulation of Lgr5+ intestinal stem cells. Cell Stem Cell 20, 801–816 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lupo, B. et al. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Sci. Transl Med. 12, eaax8313 (2020).

CAS  PubMed 

留言 (0)

沒有登入
gif